ACAD Stock Tumbles Today: Analysts Weigh RADIANT Results, Cut Price Targets
Acadia Pharmaceuticals (ACAD) stock fell 5% after analysts cut price targets following Phase 2 RADIANT trial results for Remlifanserin in Alzheimer's disease psychosis. The trial missed the primary endpoint but showed promise in a subgroup. Analysts from Needham, Deutsche Bank, BMO Capital, and Citizens lowered targets but maintained positive ratings, citing future potential.
How this was made
The 30-second read
Why it matters
The trial miss triggered a 5% stock drop and multiple downward target adjustments, indicating near‑term bearish pressure.
Market read
Analyst target cuts after trial miss suggest short‑term downside for ACAD and may influence peer biotech valuations.
What to watch
Potential for Remlifanserin in Lewy Body Dementia could offset the AD‑psychosis miss.
Background
Acadia Pharmaceuticals reported Phase 2 results for its Remlifanserin program, prompting analyst target revisions.
Ticker impact
Analysts cut ACAD price targets after Phase 2 RADIANT trial missed primary endpoint.
Expect further downside pressure, 3‑5% decline over next few days.
Multiple analysts lowered targets, and the stock is already down 5% on the news.
Market effects
Alzheimer's disease psychosis drug pipeline faces heightened scrutiny, may affect peer biotech stocks.
U.S. biotech sector could see modest pullback as investors reassess Phase 2 data risk.
Limited to biotech investors; no broad macro impact.
Counterpoint
Post‑trial data still shows a significant secondary endpoint; long‑term upside if Phase 3 succeeds.
Key entities
- companyAcadia Pharmaceuticals
Biotech firm developing Remlifanserin for neuropsychiatric indications.
- analyst_firmNeedham
Lowered ACAD price target to $35 from $41.
